Mendel Biotechnology and MEDINA to Collaborate
News Jul 23, 2013
Biostimulants are a new category of agricultural chemicals derived from natural sources and applied as seed treatments or foliar applications to improve crop productivity through improved stress tolerance, water and nutrient use efficiency, and overall growth and yield. These natural products can be brought to the market more quickly and with lower regulatory costs than synthetic chemistries.
Under the agreement, MEDINA will provide Mendel with microbial extracts from elite culture collections. Mendel will run its proprietary screens on these collections to identify natural products with crop performance benefits. Those that enhance drought tolerance and increase yield are targeted as the first products from these screens.
"We are very pleased to have identified a partner for the use of our collections to develop novel products for agriculture”, said Olga Genilloud, MEDINA’s Scientific Director. "Mendel’s screening systems offer an outstanding platform to discover novel natural products from our unique collections of microorganisms.”
"We are excited to access collections from MEDINA," said Neal Gutterson, CEO, Mendel. "The screening of their unique collections using Mendel’s proprietary, high throughput Productivity Report Panel will yield new biostimulant products. These new products offer a sustainable, environmentally-friendly means of enhancing crop productivity in broad acre and specialty crops worldwide."
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018